Browse the corpus

Walk the evidence base by book and chapter — the raw source passages that ground Ask, Differential, and the rest.

• A Phase II/III, Multicenter, Observer-blinded, Randomized, Non-inferiority and Safety, study of typhoid conjugate vaccine (EuTCV) compared to Typbar-TCV® in healthy 6 Months-45 years aged participants1 passage
• A behavioral economics intervention to increase pertussis vaccination among infant caregivers: A randomized feasibility trial1 passage
• A case for preART-adjusted endpoints in HIV therapeutic vaccine trials1 passage
• A phase 1 study of safety and immunogenicity following intradermal administration of a tetravalent dengue vaccine candidate1 passage
• A phase 1, randomized, placebo-controlled, dose-ranging study to evaluate the safety and immunogenicity of an mRNA-based chikungunya virus vaccine in healthy adults1 passage
• A phase 2b randomized, controlled trial of the efficacy of the GMZ2 malaria vaccine in African children1 passage
• A phase 2b, Randomized, double blinded comparison of the safety and efficacy of the monoclonal antibody mixture SYN023 and human rabies immune globulin in patients exposed to rabies1 passage
• A phase 3 clinical trial of MINHAI PCV13 in Chinese children aged from 7 months to 5 years old1 passage
• A phase I, randomized, placebo-controlled, double-blind, ascending-dose and single-center study to evaluate immunogenicity and safety of a live attenuated tetravalent dengue vaccine (KD-382) in Flavivirus antibody-naïve healthy adults1 passage
• A randomized non-inferiority clinical study to assess post-exposure prophylaxis by a new purified vero cell rabies vaccine (Rabivax-S) administered by intramuscular and intradermal routes1 passage
• A randomized open-label trial of 2-dose or 3-dose pre-exposure rabies prophylaxis among Thai children1 passage
• A randomized phase 3 trial of the immunogenicity and safety of coadministration of a live-attenuated tetravalent dengue vaccine (TAK-003) and an inactivated hepatitis a (HAV) virus vaccine in a dengue non-endemic country1 passage
• A systematic literature review of the effectiveness of tick-borne encephalitis vaccines in Europe1 passage
• A systematic review of knowledge, attitudes, and behaviour towards Japanese encephalitis vaccination1 passage
• Adult vaccination uptake strategies in low- and middle-income countries: A systematic review1 passage
• Adverse events following immunization (AEFI) with fractional one-fifth and one-half doses of yellow fever vaccine compared to full dose in children 9-23 months old in Uganda, 2019-2020 - Preliminary report1 passage
• An open-label, comparative, single dose, clinical Phase Ⅰ study to assess the safety and immunogenicity of typhoid conjugate vaccine (Vi-CRM197) in healthy Filipino adults1 passage
• CD11a and CD49d enhance the detection of antigen-specific T cells following human vaccination1 passage
• Case fatality rates of invasive meningococcal disease by serogroup and age: A systematic review and meta-analysis1 passage
• Characteristics of successful and unsuccessful strategies to increase vaccine intention and improve vaccine uptake for U.S. adult populations in the Affordable Care Act era (2010-2025): a systematic review and meta-regression1 passage
• Cost-effectiveness modelling studies of all preventive measures against rabies: A systematic review1 passage
• Cost-effectiveness of adult vaccinations: A systematic review1 passage
• Early onset of protection of the TAK-003 dengue vaccine: Data from the DEN-301 clinical trial1 passage
• Effect of immune regulatory pathways after immunization with GMZ2 malaria vaccine candidate in healthy lifelong malaria-exposed adults1 passage
• Efficacy of lidocaine spray for pain reduction during rabies immunoglobulin infiltration: a double-blind, randomized, placebo-controlled trial1 passage
• Enhancing uptake of respiratory vaccinations in asthma and chronic obstructive pulmonary disease (COPD) patients: a systematic review1 passage
• Evaluation of the impact of different notification methods for unvaccinated individuals in a ACWY meningococcal vaccination campaign1 passage
• Expected endpoints from future chikungunya vaccine trial sites informed by serological data and modeling1 passage
• Extended follow-up of children in a phase2b trial of the GMZ2 malaria vaccine1 passage
• Factors influencing rabies vaccines immunogenicity during post-exposure prophylaxis: a systematic literature search and meta-analysis1 passage
• Fatal outcomes following immunization errors as reported to the EudraVigilance: A case series1 passage
• Humoral and cellular responses to a tetravalent dengue vaccine (TAK-003) in adults from a dengue non-endemic region: An open-label phase 2 trial1 passage
• Immune non-interference and safety study of Vi-DT typhoid conjugate vaccine with a measles, mumps and rubella containing vaccine in 9-15 months old Nepalese infants1 passage
• Immune responses in children after vaccination with a typhoid Vi-tetanus toxoid conjugate vaccine in Bangladesh1 passage
• Immunogenicity after pre- and post-exposure rabies vaccination: A systematic review and dose-response meta-analysis1 passage
• Immunogenicity and safety of a nine-valent human papillomavirus vaccine in women 27-45 years of age compared to women 16-26 years of age: An open-label phase 3 study1 passage
• Immunogenicity and safety of a tetravalent dengue vaccine and a bivalent HPV vaccine given concomitantly or sequentially in girls aged 9 to 14 years in Mexico1 passage
• Immunogenicity and safety of serum-free rabies vaccine for human use with simulated post-exposure schedules: A randomized, double-blind, active-controlled phase III clinical trial1 passage
• Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to 23-valent pneumococcal polysaccharide in immunocompetent adults: A systematic review and meta-analysis1 passage
• Immunogenicity and safety of the live-attenuated tetravalent dengue vaccine (TAK-003) co-administered with recombinant 9-valent human papillomavirus vaccine1 passage
• Immunogenicity and safety of two-visit, intradermal pre-exposure rabies prophylaxis simultaneously administrated with chimeric live-attenuated Japanese encephalitis vaccine in children living in rabies and Japanese encephalitis endemic country1 passage
• Immunogenicity of pre-exposure rabies vaccination comparing number of doses and routes of administration: A systematic review and meta-analyses1 passage
• Immunogenicity, safety and reactogenicity of a Phase II trial of Vi-DT typhoid conjugate vaccine in healthy Filipino infants and toddlers: A preliminary report1 passage
• Impact of patient and provider nudges on addressing herpes zoster vaccine series completion1 passage
• Incidence and bacterial etiology of acute otitis media in children in the pneumococcal conjugate vaccine era: A systematic literature review and meta-analysis1 passage
• Intradermal post-exposure rabies vaccination with purified Vero cell rabies vaccine: Comparison of a one-week, 4-site regimen versus updated Thai Red Cross regimen in a randomized non-inferiority trial in the Philippines1 passage
• Knowledge, attitudes and practices on adolescent vaccination among adolescents, parents and teachers in Africa: A systematic review1 passage
• Neonatal infections: Case definition and guidelines for data collection, analysis, and presentation of immunisation safety data1 passage
• Neutralizing antibody activity, safety and immunogenicity of human anti-rabies virus monoclonal antibody (Ormutivimab) in Chinese healthy adults: A phase Ⅱb randomized, double-blind, parallel-controlled study1 passage
• One-week intramuscular or intradermal pre-exposure prophylaxis with human diploid cell vaccine or Vero cell rabies vaccine, followed by simulated post-exposure prophylaxis at one year: A phase III, open-label, randomized, controlled trial to assess immunogenicity and safety1 passage
• Persistence of antibodies, boostability, and interchangeability of Japanese encephalitis vaccines: A systematic review and dose-response meta-analysis1 passage
• Persistence of immune responses 5 years after vaccination with a single dose of typhoid conjugate vaccine (TCV) in Nepalese children1 passage
• Persistence of immunity to conjugate and polysaccharide pneumococcal vaccines in frail, hospitalised older adults in long-term follow up1 passage
• Phase I, randomized, observer-blind, placebo-controlled studies to evaluate the safety, reactogenicity and immunogenicity of an investigational non-typeable Haemophilus influenzae (NTHi) protein vaccine in adults1 passage
• Postmarketing safety surveillance of high-dose quadrivalent influenza vaccine: Reports to the Vaccine Adverse Event Reporting System1 passage
• Rabies post-exposure prophylaxis: A systematic review on abridged vaccination schedules and the effect of changing administration routes during a single course1 passage
• Randomized, blind, controlled phase III clinical trial: Assessing the immunogenicity and safety of freeze-dried human rabies vaccine (vero cell) with a 4-dose regimen (2-1-1) in a 10-60 year-old demographic1 passage
• Randomized, double-blind, placebo-controlled, phase 3 trial to demonstrate lot-to-lot consistency of 3 lots of the simplified formulation of Butantan-dengue vaccine1 passage
• Real-world vaccine effectiveness of typhoid conjugate vaccine in children and adolescents: a systematic review and meta-analysis1 passage
• Risk of bursitis and other injuries and dysfunctions of the shoulder following vaccinations1 passage
• Safety and immunogenicity of a Vi-DT typhoid conjugate vaccine: Phase I trial in Healthy Filipino adults and children1 passage
• Safety and immunogenicity of a serum-free purified Vero rabies vaccine in healthy adults: A randomised phase II pre-exposure prophylaxis study1 passage
• Safety and immunogenicity of human rabies vaccine for the Chinese population after PEP: A systematic review and meta-analysis1 passage
• Safety, immunogenicity and immune persistence of a lyophilized purified human diploid cells rabies vaccine following rabies PEP regimen Essen and Zagreb: A randomized, blinded controlled phase 3 trial in healthy participants aged 10-60 years old1 passage
• Serum-free purified Vero rabies vaccine is safe and immunogenic in children: Results of a randomized phaseII pre-exposure prophylaxis regimen study1 passage
• Single-visit, 4-site intradermal (ID) rabies vaccination induces robust immune responses 5 years after 1-week, 4-site ID primary post-exposure prophylaxis in the Philippines1 passage
• Strain-specific Plasmodium falciparum multifunctional CD4(+) T cell cytokine expression in Malian children immunized with the FMP2.1/AS02A vaccine candidate1 passage
• Systematic review of health economic evaluation studies of dengue vaccines1 passage
• The efficacy and safety of SYN023 (Zamerovimab and Mazorelvimab injection), the recombinant humanized anti-rabies virus monoclonal antibody mixture, combined with rabies vaccine in a WHO category III rabies post-exposure population: A randomized, double-blind, positive control, phase III clinical trial1 passage
• The impact of pneumococcal vaccination and nasopharyngeal colonization on the performance of a serotype-specific urine antigen detection (SSUAD) assay1 passage
• The impact of transmission dynamics of rabies control: Systematic review1 passage
• Using the 4 Pillars™ Practice Transformation Program to increase adult Tdap immunization in a randomized controlled cluster trial1 passage
• Vaccination against chikungunya - a systematic review on the immunogenicity, tolerability, and safety of the live-attenuated vaccine (LAV) Ixchiq and the virus like particle (VLP) vaccine Vimkunya1 passage
• Vaccine-preventable disease incidence of pneumococcal conjugate vaccine in the Finnish invasive pneumococcal disease vaccine trial1 passage